Navigation Links
Targeting cancerous vessels
Date:1/4/2010

By lowering the level of a neuronal protein, researchers halted the growth of blood vessels that tumors rely on for survival. The findings are reported online in the Journal of Experimental Medicine (www.jem.org) on Jan. 4.

Formerly known for its effects on neuronal growth, the team found that the protein {delta}-catenin is also produced by cells in human blood vessels. By diminishing {delta}-catenin expression, the team disrupted vessel development, or angiogenesis, associated with inflammation in tumors and wounds. As expected, samples of human lung tumors expressed more {delta}-catenin than the surrounding tissues. And normal angiogenesis remained the same regardless of {delta}-catenin.

Because blocking {delta}-catenin stunts only inflammation-induced angiogenesis, the protein may be a promising anti-cancer target, says Charles Lin, an author on the study at Vanderbilt University Medical Center in Tennessee.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Page: 1

Related medicine news :

1. Targeting brain cancer cell metabolism may provide new treatment
2. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
3. First live targeting of tumors with RNA-based technology
4. Wistar researchers show targeting normal cells in tumors slows growth
5. Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy's Video-Based Situational Assessments
6. DNA test could be key to targeting treatments for head and neck cancer
7. Another Report Finds Swine Flu Targeting the Young
8. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
9. HIV Atlas Shows Virus Targeting Minorities
10. Targeting tumor behavior may lead to new liver cancer drugs
11. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Targeting cancerous vessels
(Date:7/29/2015)... ... , ... According to the Miami Herald on July 18th acupuncture ... disorders. Acu-detox may begin taking off in the South Florida community as more detox ... acupuncture is not a new practice, it is not widely used, but has yielded ...
(Date:7/29/2015)... ... July 29, 2015 , ... San Fernando Valley skin doctor ... a limited time only, patients can get the complete treatment process with a 10 ... prefer a non-invasive treatment and have loose or sagging skin. , As the ...
(Date:7/29/2015)... ... 29, 2015 , ... Today marks a significant achievement in bringing new monies ... and is led by a group of experienced investors, has tapped into an investor ... dollars to be a part of the fund. The Sofia Fund II is ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... CanAm Enterprises, ... by USCIS over the past month! I-829 approvals have been granted to investors in ... Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention ...
(Date:7/29/2015)... CA (PRWEB) , ... July 29, 2015 , ... ... Honduras with the Hackett Hemwall Foundation in March, Steven W. Meier M.D., a ... bono prolotherapy treatments to qualifying patients with demonstrated financial need. , “We are ...
Breaking Medicine News(10 mins):Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2
... horticultural production, growers often depend on systems that use ... are efficient, fluorescent lamps can produce plants with shorter ... indicated that this reduced shoot elongation is due to ... lamps, which emit little far red irradiation. ...
... bypass surgery is considered the gold standard for most patients ... serious types of heart disease and one that affects thousands. ... favorable long-term outcomes for lower-risk patients with this condition who ... A more minimally invasive procedure than surgery, angioplasty ...
... 2011)The New York Stem Cell Foundation (NYSCF) has received ... launch the NYCF-Golub Stem Cell Initiative for Parkinson,s Disease. ... to use a novel approach to understand Parkinson,s disease ... a genetically diverse population of Parkinson,s patients. ...
... Children born to mothers who smoked during pregnancy have lower ... of heart attack and stroke later in life, a new ... children and found that those whose mothers smoked during pregnancy ... compared to a normal level of 1.5 mmol/L in children ...
... plays a relatively small role in a nurse,s decision ... nursing home, according to new research from Rice University, ... In a comprehensive study of certified nursing assistants, researchers ... emotional well-being are better predictors of turnover in long-term ...
... of New Hampshire has launched a joint research laboratory ... promote international research in agricultural development and the environment, ... Sciences and Agriculture (COLSA) at UNH recently. The laboratory ... Institute for Agricultural Resources and Regional Planning (IARRP) in ...
Cached Medicine News:Health News:Artificial light quality affects herbivore preference for seedlings 2Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 2Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 3Health News:The New York Stem Cell Foundation announces new initiative for Parkinson's disease 2Health News:It's not about the money for long-term care nurses 2Health News:UNH launches joint Sustainable Agro-Ecosystems Lab with Chinese Academy 2
(Date:7/29/2015)... July 29, 2015  Cepheid (Nasdaq: CPHD ... update to Xpert® Carba-R, with the addition of ... The on-demand, molecular test also detects and differentiates ... resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. ... CROs or Superbugs, are a growing and expensive ...
(Date:7/29/2015)... HERTFORDSHIRE, England and PITTSBURGH ... MYL ) today announced that it received regulatory clearance ... Regulation (EUMR) for its proposed acquisition of Perrigo Company ... Mylan,s Executive Chairman Robert J. Coury commented, ... of completing our acquisition of Perrigo and serves as ...
(Date:7/29/2015)... VIEW, Calif. , July 29, 2015  Efforts ... the growth strategy of pharmaceutical firms in ... . The realization is that an effective working capital ... pricing pressures and patent cliffs. Big pharma companies expect ... returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... SCOLR Pharma, Inc. (NYSE AMEX: DDD ... as the Chairman of its Board of Directors.  Johnson ... the Board.   Johnson previously served as ... Under Johnson,s leadership, Matrixx successfully developed and launched the ...
Cached Medicine Technology:Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3
Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... Model 4420 Colloid Osmometer. Rapid measurement ... the prediction of edema onset in ... dividing sample and reference chambers to ... vascular membrane in the establishment of ...
Medicine Products: